Aspira Women's Health INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Aspira Women's Health Inc. has entered into a Subordinated Business Loan and Security Agreement for a $1.05 million term loan to refinance existing debt and fund general corporate purposes.
Aspira Women's Health Inc. has amended its previous filing to provide details on the separation agreement with former CEO Michael Buhle, including severance and equity vesting.
Aspira Women's Health Inc. held its 2026 annual meeting, with stockholders electing directors, approving executive compensation, amending the stock incentive plan, and ratifying the independent auditor.
Aspira Womens Health Inc. announced the closing of a private placement raising approximately $1.485 million through the sale of common stock and warrants.
Aspira Women's Health Inc. has entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation to advance AI-powered diagnostics in women's health.
Aspira Women's Health has appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026.
Aspira Women's Health Inc. announced a definitive Laboratory Services Agreement with Mayo Clinic Laboratories for its Ova1Plus and OvaWatch tests.
Aspira Women's Health Inc. entered into a $1.05 million subordinated secured term loan agreement with Agile Lending, LLC for general corporate purposes, maturing in August 2026.
Aspira Women's Health details a strategic pivot to broader gynecological diagnostics, showcasing improved financial metrics and a robust product pipeline.
Aspira Women's Health Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $10.0 million in common stock, providing flexible capital access.
Aspira Women's Health Inc. has entered into a five-year laboratory services agreement with Mayo Clinic Laboratories to provide its Ova1Plus and OvaWatch tests.
Aspira Women's Health Inc. announced relatively flat Q3 2025 product revenues but significant improvements in gross margin, operating expenses, and reduced cash burn, driven by strategic shifts and cost controls.
Aspira Women's Health Inc. filed an amendment to correct the termination date of its Series A Common Stock Warrants, setting it to March 5, 2031.
Aspira Womens Health Inc. announced its upgrade from the OTCQB Venture Market to the OTCQX Best Market, effective October 14, 2025.
Aspira Women's Health Inc. amended its Series A Common Stock Warrants, fixing the exercise price at $0.35 and extending the term, while also granting purchasers board representation.
Aspira Womens Health Inc. announced a $3.06 million equity capital infusion through a private placement and warrant exercise to fund commercial activities and product development.
Aspira Womens Health Inc. has appointed Brian Hungerford as its new Chief Financial Officer and Principal Accounting Officer, effective September 2, 2025.
Aspira Womens Health Inc. announced its second quarter 2025 financial results, highlighting improved operational efficiency and reduced cash burn despite flat revenue and decreased test volumes.
Aspira Womens Health Inc. announced the appointment of Jane Pine Wood, an attorney with over 38 years of experience in healthcare law, to its Board of Directors, effective July 11, 2025.
Aspira Womens Health Inc. announced the termination of its $10 million contract with ARPA-H for the development of its ENDOinform endometriosis diagnostic test, having received $3.5 million prior to termination.
Aspira Womens Health Inc. announced that its stockholders approved all five proposals at the 2025 annual meeting, including the election of six directors, executive compensation, warrant issuance, and an increase in the stock incentive plan.
Aspira Women's Health announces improved financial results for Q1 2025, driven by increased sales productivity and cost control measures.
Aspira Womens Health Inc. received notification from Nasdaq regarding the delisting of its shares due to non-compliance with minimum stockholders' equity requirements.
8-K: Aspira Women's Health Secures $2 Million Equity Purchase Agreement and Appoints Three New Directors
Aspira Women's Health announces a $2 million equity purchase agreement with Triton Funds L.P. and the appointment of three new directors to its Board.
Aspira Womens Health Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of outstanding shares, aiming to improve meeting logistics.
Aspira Women's Health Inc. has entered into an employment agreement with Michael Buhle, appointing him as the Chief Executive Officer, effective March 26, 2025.
Aspira Women's Health announces its fourth quarter and full year 2024 financial results, highlighting record OvaSuite revenue and test volume despite overall product revenue remaining flat year-over-year.
James Crawford, VP of Finance at Aspira Women's Health Inc., has resigned for personal reasons, effective April 4, 2025.
Celeste Fralick has resigned from the Board of Directors of Aspira Women's Health, effective March 31, 2025, citing personal reasons.
Aspira Women's Health has successfully closed a $1.37 million private placement of senior secured convertible promissory notes to support its commercial activities and general corporate purposes.